Clinical Trial Search
HIV Infections
-
BP17921
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection. Completed -
ML17819
A Study of Fuzeon (Enfuvirtide) in Patients With Advanced HIV Infection Completed -
ML18018
QUALITE study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Completed -
ML18093
A Study of the Safety of Viracept (Nelfinavir) in an Expanded Access Program in HIV-1 Positive Women Who are Pregnant or Who Want to Become Pregnant. Completed -
ML18242
INDEED Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Completed -
ML18243
A Study of the Effect of Fuzeon (Enfuvirtide)-Based Therapy on Viral Load in HIV-Positive, Treatment-Naive Patients Completed -
ML18413
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Completed -
ML18596
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. Completed -
ML18634
A Study of Fuzeon (Enfuvirtide) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection Completed -
ML19233
OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon. Completed -
ML19326
ESPrES 500 Study: A Study to Evaluate the Safety of a New Tablet Formulation of Boosted Saquinavir in HIV-1 Infected Patients. Completed -
ML19712
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Completed -
ML19849
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Completed -
ML20837
AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients. Completed -
ML21287
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure. Completed -
MV16721
A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen Completed -
MV18220
A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon Completed -
MV18406
A Study to Evaluate the Safety and Efficacy of Adding Fuzeon (Enfuvirtide) to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients with Prior Treatment Experience Completed -
NP17586
A Study to Assess Fuzeon (Enfuvirtide) in Human Immunodeficiency Virus (HIV)-infected Subjects With Renal Impairment Completed -
NP25607
A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients Completed -
NV16390
A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon Completed -
NV16391
A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen Completed -
NV17658
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients Completed -
NV20911
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Completed -
WV16789
A Study of Viracept (Nelfinavir) in Patients With HIV-1 Infection Completed -
ML19355
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression. Terminated -
ML25398
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection Active, not recruiting